PerkinElmer to Expand Neonatal Screening Program in Israel; Selected by Chaim Sheba Medical Center to create a comprehensive newborn screening program.

BOSTON -- PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, today announced that its neonatal screening technology has been selected by State of Israel's Chaim Sheba Medical Center, Tel Aviv, to create a comprehensive newborn screening program that is intended to cover every child born in Israel. Under the terms of this agreement, PerkinElmer will provide the State of Israel with instrumentation, reagents, scientific expertise, and a robust informatics system that will enhance the nation's neonatal screening and data management capabilities. The contract, to be executed through PerkinElmer's regional distributors HVD Vertriebs Gmbh and Gamidor Limited, will fulfill a recent mandate by the Medical Research Infrastructure Development and Health Services Fund to substantially expand its newborn screening program to cover Israel's entire population and increase the number of tests that will be screened for indications of disease. Approximately 120,000 babies are born each year in Israel, which has a population of about 6.3 million.

"We are honored that the State of Israel has selected PerkinElmer to expand its newborn screening program," said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. "We look forward to working with the Chaim Sheba Medical Center to improve the standard of healthcare to newborns," Friel added.

As part of this agreement, Chaim Sheba will use Specimen Gate(R), PerkinElmer's screening laboratory information management system (LIMS). This software will allow Chaim Sheba to implement a comprehensive solution that will electronically track laboratory workflow from sample receipt and preparation, through the analytical steps, to quality control review, reporting and follow-up.

Israel's enhanced neonatal screening initiative will be built around PerkinElmer's AutoDELFIA(R) automatic immunoassay system. DELFIA is the leading technology for the screening of newborns for hypothyroidism, congenital adrenal hyperplasia and cystic fibrosis worldwide, and can deliver results for several tests from a single sample. The blood samples are collected from a small prick to the heel of a newborn's foot. To augment Israel's screening capacity in order to accommodate additional tests, PerkinElmer will deliver multiple AutoDELFIA units as well as reagents and equipment.

The three tests that will be sourced from PerkinElmer for Israel's expanded neonatal screening program are: 17(alpha)OH progesterone for screening congenital adrenal hyperplasia (CAH), a hormonal disorder affecting the adrenal glands; and hTSH and T4, both for screening congenital hypothyroidism (CH), which if left untreated can lead to severe mental retardation.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information

Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.